NCT06055244

Amantadine Therapy for Cognitive Impairment in Long COVID

Amantadine Therapy for Cognitive Impairment Related to Post-COVID Condition

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Ohio State University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will look at the effects of amantadine on cognitive function in persons with Long COVID. It will also collect specimens to study possible causes of cognitive symptoms in Long COVID, and whether any lab tests can predict who will respond better to amantadine.

Detailed description

This study will enroll 60 subjects with Long COVID and cognitive symptoms such as problems with memory, concentration, speech and attention, and "brain fog." Subjects will be assigned randomly to two groups. One group will be treated with amantadine, the other group will receive placebo. The study will last 4 months. During that time, subjects will be assessed at regular intervals with symptom questionnaires, cognitive tests, and lab measurements.

Conditions

• Long COVID
• Post-COVID19 Condition
• Post-Acute COVID19 Syndrome

Interventions

Type	Name	Description
DRUG	Amantadine	Subjects will be give amantadine 100 mg twice daily.

Timeline

• Start date: 2023-12-07
• Primary completion: 2025-12-11
• Completion: 2025-12-29
• First posted: 2023-09-26
• Last updated: 2026-01-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study